A prospective, open-label, observational study evaluating SYMLIN Rm [pramlintide acetate] injection use in insulin using patients with type 2 and type 1 diabetes following SYMLIN introduction into the marketplace.
Phase of Trial: Phase IV
Latest Information Update: 17 Jul 2014
At a glance
- Drugs Pramlintide (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 31 Aug 2018 Biomarkers information updated
- 30 Jun 2009 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
- 30 Jun 2009 Actual patient number (1297) added as reported by ClinicalTrials.gov.